Clinical trial · Observational
Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.
Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer
NCT02078245CI-TRIAL-00070739unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer. In this study, following the indication of the swedish guidelines, consecutive patients with a family history for pancreas cancer underwent a clinical surveillance Magnetic Resonance Imaging (MRI) based. The results of this study were analyzed looking in the patients files collected during the screening period.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hereditary Pancreatic Cancer | — | UNRESOLVED | — |
| Hereditary Pancreatitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Familial pancreatic cancer patients
- description
- Individual with ten fold higher risk to develop pancreatic cancer.
- interventionNames
- Other: MRI
Primary outcomes (1)
- measure
- MRI accuracy
- timeFrame
- Three years
- description
- MRI accuracy in detection precancerous pancreatic lesions.
Secondary outcomes (2)
- measure
- Definition of spectrum of precancerous pancreatic lesions
- timeFrame
- During three years
- measure
- Outcome of surveillance program
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 10 fold higher risk to develop pancreatic cancer * Obtained informed consent Exclusion Criteria: * age less than 18 yrs * No consensus obtained
References
Publications (6)
- BACKGROUNDCanto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 Mar;62(3):339-47. doi: 10.1136/gutjnl-2012-303108. Epub 2012 Nov 7. PMID 23135763
- BACKGROUNDBartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P. Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer. 2013 Mar;12(1):89-96. doi: 10.1007/s10689-012-9582-y. PMID 23179793
- RESULTPozzi Mucelli RM, Moro CF, Del Chiaro M, Valente R, Blomqvist L, Papanikolaou N, Lohr JM, Kartalis N. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria? Eur Radiol. 2022 Aug;32(8):5144-5155. doi: 10.1007/s00330-022-08650-5. Epub 2022 Mar 11. PMID 35275259
- RESULTDel Chiaro M, Ateeb Z, Hansson MR, Rangelova E, Segersvard R, Kartalis N, Ansorge C, Lohr MJ, Arnelo U, Verbeke C. Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience. Ann Surg Oncol. 2017 Apr;24(4):1120-1126. doi: 10.1245/s10434-016-5661-x. Epub 2016 Nov 7. PMID 27822633
- RESULTCapurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M. Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals. World J Gastrointest Endosc. 2015 Jul 25;7(9):833-42. doi: 10.4253/wjge.v7.i9.833. PMID 26240684
- RESULTDel Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J, Haas SL, Segersvard R, Andren-Sandberg A, Lohr JM. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. JAMA Surg. 2015 Jun;150(6):512-8. doi: 10.1001/jamasurg.2014.3852.